Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amantadine ER for levodopa-induced dyskinesia in Parkinson's disease
2014-001132-10Phase 3Terminated
- Sponsor
- Osmotica Pharmaceuticals
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing Amantadine ER with Placebo (2 arms). Primary endpoint: Change from baseline to Day 98 in Unified Dyskinesia Rating Scale total score. Started Sep 2014; status: terminated.
02
Drugs
amantadine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2014-001132-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001132-10.